Valuation: Indivior

Market Cap 4.61B 3.94B 3.68B 3.38B 6.35B 441B 6.47B 43.66B 17.02B 221B 17.3B 16.92B 731B P/E 2026 *
10.5x
P/E 2027 * 9.51x
Enterprise Value 4.59B 3.93B 3.67B 3.37B 6.33B 440B 6.45B 43.54B 16.97B 220B 17.25B 16.88B 729B EV / Sales 2026 *
3.45x
EV / Sales 2027 * 2.88x
Free-Float
97.98%
Yield 2026 *
-
Yield 2027 * -
Change 5-day change 1-year change 3-year change Capi.($)
+0.09%+1.57% - - 4.61B
-2.81%+2.93%+76.40%+126.23% 1,141B
-2.21%+2.02%+49.50%+59.77% 659B
-1.56%+4.39%+25.19%+74.37% 470B
+1.20%+1.72%+42.89%+45.78% 366B
-0.61%+1.72%+25.21%+41.34% 302B
+0.32%+3.30%+2.60%+13.42% 254B
-1.95%+3.80%+46.31%+66.37% 239B
-1.10%-1.12%-14.91%-52.66% 207B
-2.82%+3.84%+20.81%+88.89% 183B
Average -1.02%+4.10%+30.44%+51.50% 424.55B
Weighted average by Cap. -1.39%+4.31%+43.82%+71.26%

Financials

2026 *2027 *
Net sales 1.33B 1.14B 1.06B 976M 1.83B 127B 1.87B 12.62B 4.92B 63.87B 5B 4.89B 211B 1.4B 1.2B 1.12B 1.03B 1.93B 134B 1.97B 13.26B 5.17B 67.11B 5.25B 5.14B 222B
Net income 474M 406M 379M 348M 653M 45.38B 666M 4.49B 1.75B 22.74B 1.78B 1.74B 75.29B 530M 454M 423M 388M 730M 50.71B 744M 5.02B 1.96B 25.41B 1.99B 1.95B 84.14B
Net Debt -12.5M -10.7M -9.99M -9.16M -17.22M -1.2B -17.56M -118M -46.18M -599M -46.94M -45.91M -1.98B -570M -488M -455M -418M -785M -54.54B -801M -5.4B -2.11B -27.33B -2.14B -2.09B -90.49B
Logo Indivior
Indivior Pharmaceuticals, Inc. is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. It sells its products in the United States and in other selected areas of the world.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-